Quest Diagnostics’ Haystack MRD test secures NYSDOH approval

Quest Diagnostics has received approval from the NYSDOH CLEP for its Haystack MRD test, expanding its use to cancer patients throughout the US. The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour disease. Haystack Oncology focuses on advancing liquid biopsy technologies. Credit: Gorodenkoff/Shutterstock.com. Quest Diagnostics has received approval from the New York State Department of Health’s (NYSDOH) Clinical Laboratory Evaluation Programme for its Haystack minimal residual disease (MRD) test, expanding its use to cancer patients throughout the US. The clearance enables clinicians in New York to access the Haystack MRD…

Source: Medical Device Network